variable. It is only through more logical and thoughtful considerations that better treatment decisions will be made and patient outcomes enhanced. Future research in this area need to move towards evaluating therapeutic approaches based on 'significance of PDA shunting' rather than its mere presence.
Reply to McNamara and Jain
Journal of Perinatology (2013) 33, 249; doi:10.1038/jp.2012.106
We thank Drs McNamara and Jain for their thoughtful letter and recognize their important contributions to our understanding of patent ductus arteriosus (PDA) physiology. 1 On the whole, my coauthors and I agree with their salient points: (1) deleterious effects of a PDA are likely related to the magnitude and duration of the left-to-right shunt, and these data are generally not documented in PDA publications (including ours, although we made some progress in this regard), (2) small restrictive PDAs likely have been overtreated in past years (and our study specifically avoided this pitfall), (3) standardizing the definition of hemodynamic significance is paramount to refining rational PDA therapy.
A few points of clarification are important in regard to their questions. First, we clearly specify in the Methods that our investigation was prospectively designed to be 18 months. This was done not for convenience, but because we wanted a sufficient number of VLBW infants with PDAs treated with the new permissive protocol, to compare with the 139 control PDA infants born in the previous 36 months, a time period when cardiorespiratory therapy was traditional and relatively uniform. We were appropriately cautious as we wanted to minimize potential deleterious events related to untreated PDAs, yet have enough patients to make meaningful comparisons between Era 1 and Era 2. This was uncharted waters and there was some reticence. We think we struck a reasonable balance and our investigation is the largest published study that carefully documents a wide variety of NICU outcomes related to permissive PDA therapy.
Second, the major finding of our study (a higher rate of the combined outcome of death or chronic lung disease in Era 2) is concerning, and clearly stated in both the Results and Discussion. We write that this is both biologically plausible and an urgent issue to clarify in a RCT. We concur that clinical and echocardiographic staging of the PDA would be a wise way to parcel the study infants, something that has not been done as yet. Our Era 2 experience does lend support to a permissive PDA arm in a RCT (see Figure 1) , ideally enhanced by the hemodynamic staging that Drs McNamara and Jain suggest. Of note, Sosenko et al. 2 have recently published a small RCT showing that delayed pharmacologic closure therapy until a 'hemodynamically significant' PDA was present did not improve or worsen NICU outcomes. Echocardiographic staging of the type Drs McNamara and Jain suggest was not documented.
Third, although fluid status may indeed affect end-organ perfusion, we doubt the statistically significant Era 2 decrease of 10 ml kg À 1 /day in total fluids on days 1-28 was clinically significant. Fourth, Drs McNamara and Jain will be interested to know that based upon our initial study (essentially a reasoned quality improvement project), we have extended the analysis of our permissive PDA therapy to three additional NICUs, which has increased our total number of PDA infants from 211 to 369. This larger experience will shed light on rational PDA therapy and has been submitted for publication.
